January 10, 2018 / 2:51 PM / 10 months ago

BRIEF-GenSight Biologics Receives MHRA Approval To Initiate Phase I/II Pioneer Clinical Trial Of GS030 Gene Therapy In Retinitis Pigmentosa

Jan 10 (Reuters) - Gensight Biologics SA:

* GENSIGHT BIOLOGICS RECEIVES MHRA APPROVAL TO INITIATE PHASE I/II PIONEER CLINICAL TRIAL OF GS030 GENE THERAPY IN RETINITIS PIGMENTOSA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below